CorMedix Inc. (CRMD)
$7.39-0.94%Close
SELLBEAR · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $580M
- Beta
- 1.41
- P/E (TTM)
- 3.07
- Short % float
- 23.18%
- Days to cover
- 18.9
- SI change
- -4.8%
- 1W
- +1.51%
- 1M
- -6.34%
- vs SPY 1W
- +1.09%
- vs SPY 1M
- -8.40%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 41
- VALUE
- 36
- GROWTH
- 73
- GARP
- 14
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC26.8%
REV YoY-
ROE44.6%
EPS YoY-
ROA20.7%
GROSS83
OP47
NET40
[VALUATION]
P/E TTM3.07
P/E FWD147.59
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.26
P/FCF-
EV/EBITDA1.87
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E31.50
ALTMAN Z-
CURR RATIO2.56
ND/EBITDA-
BETA1.41
Company news
FAQ
- What is LOPJLB’s current signal on CRMD?
- LOPJLB’s latest quantitative signal on CorMedix Inc. (CRMD) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is CRMD in?
- CorMedix Inc. (CRMD) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does CorMedix Inc. (CRMD) do?
- CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-…